Korea

Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.

Angus Liu Sep 25, 2026 9:38am

Samsung Bio nets $262M manufacturing deal with unnamed pharma

Sep 10, 2026 7:36am

SK Pharmteco cuts ribbon on 2 new API plants in Ireland

Aug 19, 2026 11:00am

Korea's Celltrion throws down $330M for Lilly plant in N.J.

Sep 23, 2025 9:24am

Samsung Bio inks US contract manufacturing deal worth $1.3B

Sep 9, 2025 8:52am

bidding action plant purchase bidding war

Celltrion nears US plant purchase to offset tariff threats

Jul 30, 2025 2:56pm